Traynor Capital Management Inc. Purchases 16,161 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Traynor Capital Management Inc. raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 80.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 36,363 shares of the medical equipment provider’s stock after purchasing an additional 16,161 shares during the quarter. Intuitive Surgical accounts for about 1.1% of Traynor Capital Management Inc.’s investment portfolio, making the stock its 13th biggest holding. Traynor Capital Management Inc.’s holdings in Intuitive Surgical were worth $17,864,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares during the period. Capital World Investors grew its stake in shares of Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares during the period. Jennison Associates LLC grew its position in Intuitive Surgical by 4.6% during the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after buying an additional 198,483 shares during the period. American Century Companies Inc. grew its position in Intuitive Surgical by 3.0% during the second quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock valued at $1,066,837,000 after buying an additional 70,556 shares during the period. Finally, Clearbridge Investments LLC grew its position in Intuitive Surgical by 1.6% during the second quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock valued at $881,380,000 after buying an additional 30,449 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In other news, EVP Brian Edward Miller sold 2,553 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total value of $1,314,795.00. Following the transaction, the executive vice president now directly owns 7,066 shares in the company, valued at approximately $3,638,990. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, SVP Mark Brosius sold 2,128 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total value of $1,095,920.00. Following the completion of the sale, the senior vice president now directly owns 273 shares of the company’s stock, valued at $140,595. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian Edward Miller sold 2,553 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total transaction of $1,314,795.00. Following the completion of the sale, the executive vice president now directly owns 7,066 shares of the company’s stock, valued at approximately $3,638,990. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,838 shares of company stock worth $25,241,950. Insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Evercore ISI restated a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Piper Sandler restated an “overweight” rating and set a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. Wells Fargo & Company boosted their target price on shares of Intuitive Surgical from $466.00 to $549.00 and gave the company an “overweight” rating in a research report on Friday, October 18th. Citigroup boosted their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, Morgan Stanley lifted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Trading Down 0.1 %

NASDAQ ISRG opened at $510.88 on Tuesday. The company’s 50-day moving average price is $488.56 and its 200-day moving average price is $443.89. The stock has a market cap of $181.97 billion, a PE ratio of 82.14, a PEG ratio of 5.11 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $523.34.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.